On 25 November 2025, Sanofi entered into a share purchase agreement to sell a 70% stake in the company operating its Lüleburgaz pharmaceutical manufacturing facility to Fareva, a world leader in industrial subcontracting for the pharmaceuticals, cosmetics, and industrial & household sectors. Sanofi will retain a 30% minority stake in the company.
The Lüleburgaz facility is one of Türkiye’s leading pharmaceutical manufacturing sites, with significant production capacity and export capabilities. The transaction is expected to close upon completion of customary regulatory approvals, including clearance from the Turkish Competition Authority.
Paksoy is pleased to announce that a team consisting of partner Stéphanie Beghe Sönmez, along with counsel Zeynep Toma and associates Selen Toma and Cansın Taner, is acting as counsel to Sanofi on this transaction.